Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

CVRx

CVRx?uq=UG6efJS6
2001 FOUNDED
PRIVATE STATUS
71-80 EMPLOYEES
Series G LATEST DEAL TYPE
$113M LATEST DEAL AMOUNT
16 INVESTORS
Description

Developer of implantable technology designed to provide treatment of high blood pressure. The company has developed Barostim neo which is designed to trigger the body's own natural blood flow regulation system to treat high blood pressure and heart failure, enabling patients to begin treatment more quickly and result in a higher likelihood of a successful treatment.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Devices and Supplies
Surgical Devices
Primary Office
  • 9201 West Broadway Avenue
  • Suite 650
  • Minneapolis, MN 55445
  • United States

+1 (763) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore CVRx’s full profile, request a free trial.

CVRx Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series G) 05-Aug-2016 $113M 00000 00000 Completed Generating Revenue
7. Debt - General 22-Sep-2014 00000 Completed Generating Revenue
6. Later Stage VC (Series F) 30-Oct-2013 0000 00000 00000 Completed Generating Revenue
5. Later Stage VC (Series E) 30-Jul-2008 000.00 00000 00000 Completed Startup
4. Later Stage VC (Series D) 09-May-2007 0000 00000 00000 Completed Startup
3. Later Stage VC (Series C) 11-May-2006 000.00 000.00 0000 Completed Startup
2. Early Stage VC (Series B) 21-May-2003 $22.3M $30.4M 000.00 Completed Startup
1. Early Stage VC (Series A) 27-Jun-2001 $8.02M $8.02M 0000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

CVRx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series G 000,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series F2 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series E2 00,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series D2 0,000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series C2 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B2 2,963,069 $0.010000 8% $2.54 $2.54 1x $2.54 1.37%
Series A2 2,454,686 $0.010000 8% $2 $2 1x $2 1.14%
To view this company’s complete Cap Table, request access »

CVRx Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Action Potential Venture Capital Venture Capital Minority 000 0000 000000 0
Gilde Healthcare Partners Venture Capital Minority 000 0000 000000 0
Windham Venture Partners Venture Capital Minority 000 0000 000000 0
DaVita PE-Backed Company Minority 000 0000 000000 0
Sterling Capital Funds Fund of Funds Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

CVRx Executive Team (8)

Name Title Board
Seat
Contact
Info
Nadim Yared President, Chief Executive Officer & Board Member
John Brintnall Chief Financial Officer & Vice President, Finance & Administration
Jared Oasheim Controller
Phillipe Wanstok Ph.D Chief Commercial Officer
Joseph DuPay Senior Vice President, Development & Operations

1 Former Executive

You’re viewing 5 of 8 executives. Get the full list »

CVRx Board Members (16)

Name Representing Role Since Contact
Info
Ali Behbahani MD New Enterprise Associates Board Member 000 0000
Geoffery Pardo Gilde Healthcare Partners Board Member 000 0000
John Nehra New Enterprise Associates Board Member 000 0000
Joseph Slattery Self Board Member 000 0000
Kadir Kadhiresan Ph.D Johnson & Johnson Innovation - JJDC Board Member 000 0000

9 Former Board Members

You’re viewing 5 of 16 board members. Get the full list »